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Disentangling receptor kinetics and network dynamics is
a prerequisite for understanding and predicting the sys-
temic effects of pharmacological compounds. These
effects may result from a complex balance between acti-
vation and desensitization of various receptor subtypes
that can be located on excitatory or inhibitory neurons or
their afferent fibres. We therefore combined receptor and
network modelling [1] to explain the suppressive effect
that TC-7020 [2,3], a partial agonist of a7-type nicotinic
acetylcholine receptors (nAChRs), was observed to exert
on the release of dopamine (DA) in the nucleus accum-
bens of anesthetized rats. As nAChRs are ion channels
permeating Na+ and Ca2+, and as i.v. injection of nicotine
itself enhanced DA release, partial agonists would rather
be expected to enhance DA release as well.
Using the model, we evaluated several potential effects
of TC-7020 on DA-ergic and GABA-ergic neurons in the
ventral tegmental area (VTA) and its glutamatergic affer-
ents from neocortex. Potential effects of TC-7020 included
on the one hand a reduced nAChR channel conductance
on DA neurons through competitive or non-competitive
inhibition, or through receptor desensitization. On the
other hand, enhancing the nAChR conductance on
GABA-neurons (through direct activation of nAChRs, or
through priming of their response to background ACh [4])
could have produced, through inhibition of DA neurons, a
similar suppressive effect on DA release. The model
showed that rapid desensitization of the a7 nAChRs on
DA neurons explained both the sign and time-course of
the voltammetric DA response, provided that a back-
ground cholinergic tone was present that contributed, by
activating a7 nAChRs without desensitizing them, to the
baseline level of DA release.
Another surprising finding of the voltammetric DA
recordings was that PNU-120596, a positive allosteric
modulator of a7 nAChRs, prevented and abolished the
effect of TC-7020 on DA release, instead of amplifying it.
The model proposes two possible but contrasting
mechanisms: a well-established relieve of a7 nAChRs
from the weak state of desensitization into which they
were brought by TC-7020, or, in contrast, the induction
of a strong desensitization in a7 nAChRs due to channel
over-excitation by background ACh under the amplifying
effect of PNU-120596 [5].
These results show that tonic levels of neurotransmitters
and neuromodulators like acetylcholine and dopamine
may profoundly affect the dynamics, and hence the sys-
temic effect, of pharmacological compounds. As these
background levels may be altered in in-vitro preparations,
circuit modelling may become an indispensible tool in
drug development.
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